268 related articles for article (PubMed ID: 24938563)
21. Comparative risk of incident venous thromboembolism in patients with inflammatory bowel disease initiating tumour necrosis factor-α inhibitors or nonbiologic agents: a cohort study.
Desai RJ; Gagne JJ; Lii J; Liu J; Friedman S; Kim SC
CMAJ; 2017 Nov; 189(47):E1438-E1447. PubMed ID: 29180383
[TBL] [Abstract][Full Text] [Related]
22. Incidence, management, and course of cancer in patients with inflammatory bowel disease.
Algaba A; Guerra I; Marín-Jiménez I; Quintanilla E; López-Serrano P; García-Sánchez MC; Casis B; Taxonera C; Moral I; Chaparro M; Martín-Rodríguez D; Martín-Arranz MD; Manceñido N; Menchén L; López-Sanromán A; Castaño Á; Bermejo F
J Crohns Colitis; 2015 Apr; 9(4):326-33. PubMed ID: 25687203
[TBL] [Abstract][Full Text] [Related]
23. Absolute and Relative Risk of New-Onset Psoriasis Associated With Tumor Necrosis Factor-α Inhibitor Treatment in Patients With Immune-Mediated Inflammatory Diseases: A Danish Nationwide Cohort Study.
Thein D; Egeberg A; Skov L; Loft N
JAMA Dermatol; 2022 Sep; 158(9):997-1004. PubMed ID: 35767240
[TBL] [Abstract][Full Text] [Related]
24. Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases.
Singh S; Iversen AT; Allin KH; Jess T
JAMA Netw Open; 2022 Sep; 5(9):e2234200. PubMed ID: 36178685
[TBL] [Abstract][Full Text] [Related]
25. Birth Outcomes in Children Fathered by Men Treated with Anti-TNF-α Agents Before Conception.
Larsen MD; Friedman S; Magnussen B; Nørgård BM
Am J Gastroenterol; 2016 Nov; 111(11):1608-1613. PubMed ID: 27619836
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of anti-tumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases.
Bank S; Andersen PS; Burisch J; Pedersen N; Roug S; Galsgaard J; Turino SY; Brodersen JB; Rashid S; Avlund S; Olesen TB; Green A; Hoffmann HJ; Thomsen MK; Thomsen VØ; Nexø BA; Vogel U; Andersen V
Dan Med J; 2015 Mar; 62(3):. PubMed ID: 25748864
[TBL] [Abstract][Full Text] [Related]
27. Psychological stress and inflammatory bowel disease: a follow-up study in parents who lost a child in Denmark.
Li J; Nørgard B; Precht DH; Olsen J
Am J Gastroenterol; 2004 Jun; 99(6):1129-33. PubMed ID: 15180736
[TBL] [Abstract][Full Text] [Related]
28. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study.
Jess T; Horváth-Puhó E; Fallingborg J; Rasmussen HH; Jacobsen BA
Am J Gastroenterol; 2013 Dec; 108(12):1869-76. PubMed ID: 23978954
[TBL] [Abstract][Full Text] [Related]
29. Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease.
Bank S; Andersen PS; Burisch J; Pedersen N; Roug S; Galsgaard J; Turino SY; Brodersen JB; Rashid S; Rasmussen BK; Avlund S; Olesen TB; Hoffmann HJ; Thomsen MK; Thomsen VØ; Frydenberg M; Nexø BA; Sode J; Vogel U; Andersen V
Pharmacogenomics J; 2014 Dec; 14(6):526-34. PubMed ID: 24776844
[TBL] [Abstract][Full Text] [Related]
30. Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry.
Chaparro M; Ramas M; Benítez JM; López-García A; Juan A; Guardiola J; Mínguez M; Calvet X; Márquez L; Fernández Salazar LI; Bujanda L; García C; Zabana Y; Lorente R; Barrio J; Hinojosa E; Iborra M; Cajal MD; Van Domselaar M; García-Sepulcre MF; Gomollón F; Piqueras M; Alcaín G; García-Sánchez V; Panés J; Domènech E; García-Esquinas E; Rodríguez-Artalejo F; Gisbert JP
Am J Gastroenterol; 2017 Jul; 112(7):1135-1143. PubMed ID: 28534520
[TBL] [Abstract][Full Text] [Related]
31. Use of tumour necrosis factor-α inhibitors and the risk of serious infection in paediatric inflammatory bowel disease in Denmark: a nationwide cohort study.
Wintzell V; Svanström H; Melbye M; Jess T; Olén O; Ludvigsson JF; Pasternak B
Lancet Gastroenterol Hepatol; 2019 Nov; 4(11):845-853. PubMed ID: 31494100
[TBL] [Abstract][Full Text] [Related]
32. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor.
Byun JM; Lee CK; Rhee SY; Kim HJ; Im JP; Park DI; Eun CS; Jung SA; Shin JE; Lee KM; Cheon JH
Scand J Gastroenterol; 2015 Mar; 50(3):312-20. PubMed ID: 25581784
[TBL] [Abstract][Full Text] [Related]
33. Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy.
Sherman M; Tsynman DN; Kim A; Arora J; Pietras T; Messing S; St Hilaire L; Yoon S; Decross A; Shah A; Saubermann L
J Dig Dis; 2014 Apr; 15(4):174-9. PubMed ID: 24373601
[TBL] [Abstract][Full Text] [Related]
34. Anti-TNF-α Use During the Third Trimester of Pregnancy in Women with Moderate-severe Inflammatory Bowel Disease and the Risk of Preterm Birth and Low Birth Weight.
Kammerlander H; Nielsen J; Knudsen T; Kjeldsen J; Friedman S; Nørgård BM
Inflamm Bowel Dis; 2017 Nov; 23(11):1916-1923. PubMed ID: 28858070
[TBL] [Abstract][Full Text] [Related]
35. Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors.
Segan J; Staples MP; March L; Lassere M; Chakravarty EF; Buchbinder R
Intern Med J; 2015 Mar; 45(3):310-8. PubMed ID: 25565419
[TBL] [Abstract][Full Text] [Related]
36. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
37. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.
Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven RF; Klareskog L
Ann Rheum Dis; 2007 Oct; 66(10):1339-44. PubMed ID: 17261532
[TBL] [Abstract][Full Text] [Related]
38. The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-α Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies.
Ai JW; Zhang S; Ruan QL; Yu YQ; Zhang BY; Liu QH; Zhang WH
J Rheumatol; 2015 Dec; 42(12):2229-37. PubMed ID: 26472414
[TBL] [Abstract][Full Text] [Related]
39. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH
Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144
[TBL] [Abstract][Full Text] [Related]
40. The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study.
Baars JE; Looman CW; Steyerberg EW; Beukers R; Tan AC; Weusten BL; Kuipers EJ; van der Woude CJ
Am J Gastroenterol; 2011 Feb; 106(2):319-28. PubMed ID: 21045815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
